Please login to the form below

Not currently logged in
Email:
Password:

Vikas Sinha joins Verona as non-executive director

Brings strong US and financial experience to the UK drug development firm

Verona Pharma Vikas SinhaUK drug development company Verona Pharma has appointed Vikas Sinha as a non-executive director.

Currently executive vice president and chief financial officer at Alexion Pharmaceuticals, Sinha has served at the rare disease firm since 2005.

Prior to that he spent 11 years at Bayer, holding roles in the US, Canada, Japan and Germany, latterly as chief financial officer for Bayer Pharmaceuticals Corporation in the US.

Dr David Ebsworth, chairman of Verona Pharma, said: “Vikas' impressive financial background, including his US expertise, makes him a very welcome addition to our Board of Directors. 

“I have known Vikas for many years having worked together at Bayer and hold his impressive track record in high regard. We are pleased that Vikas will be joining our Board at such a pivotal time, as we progress our lead asset, RPL554, into a phase IIb clinical trial programme.”

A potential first-in-class treatment for chronic obstructive pulmonary disease (COPD), Verona Pharma's RPL554 is being tested as a nebulised maintenance treatment for patients with moderate to severe disease.

13th September 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics